IDH2 and central nervous system cancer: In our analysis, pooled detection rates were 76% in IDH-mutant gliomas and 84% in IDH-wildtype tumors, with a non-significant trend toward higher detection in the latter (OR 0.72, 95% CI 0.26–2.02; I2 = 50.5%)The literature does not consistently demonstrate a robust difference.